Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients
Open Access
- 14 December 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 139 (1) , 152-158
- https://doi.org/10.1111/j.1365-2249.2005.02653.x
Abstract
Mitoxantrone (MX) is a cytotoxic drug with proven clinical efficacy in active multiple sclerosis (MS). In this ex vivo study we investigated the immunological effects of MX on peripheral blood leucocytes (PBL) from MS patients. PBL were isolated from 46 patients with active MS (mean age 42 years, female : male 1·4 : 1) before and immediately after 1 h MX infusion. Isolated PBL were cultured and stimulated with phytohaemagglutinin (PHA), T cell receptor stimulating monoclonal antibody (MoAb) X35 or kept in culture medium alone. Proliferation was measured by [3H]‐thymidine incorporation. MX‐uptake and cell death in PBL subpopulations was analysed by flow cytometry using antibodies against cluster of differentiation (CD)‐surface antigens, annexin V (AnnV) and propidium iodide (PI). MX was incorporated rapidly into PBL. After only a 1‐h in vivo exposure, MX reduced proliferative responses in unstimulated and stimulated PBL (PHA: − 17%, MoAb X35: − 13%). MX‐exposed PBL showed an increase of AnnV+/PI+ cells (unstimulated: 12%, PHA: 15%), which was even more pronounced 2 weeks after infusion. No difference was observed between de novo MX‐treated patients and those on long‐term MX treatment. In T cell receptor stimulated PBL, cell death was induced preferentially in CD19‐positive B cells and to a lesser extent in CD8‐positive T cells. MX is incorporated rapidly in circulating PBL of MS patients and induces a pronounced suppression of proliferative responses. This suppression appears to be mediated at least partly by the induction of late apoptotic/necrotic cell death with a preferential susceptibility of B cells.Keywords
This publication has 23 references indexed in Scilit:
- The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis [RETIRED]Neurology, 2003
- Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating EventNew England Journal of Medicine, 2003
- Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: Termination of CNS autoimmune inflammation and modulation by interferon‐betaGlia, 2003
- Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialThe Lancet, 2002
- New concepts in the immunopathogenesis of multiple sclerosisNature Reviews Neuroscience, 2002
- Escalating Immunotherapy of Multiple SclerosisEuropean Neurology, 1999
- A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin VJournal of Immunological Methods, 1995
- Treatment of multiple sclerosis with mitoxantroneArchiv Fur Psychiatrie Und Nervenkrankheiten, 1992
- Mitoxantrone affects topoisomerase activities in human breast cancer cellsBiochemical and Biophysical Research Communications, 1986
- Mitoxantrone (novantrone): a review of experimental and early clinical studiesCancer Treatment Reviews, 1983